Finally, DAB2IP and RASAL2 mutations or deletions have been reported in different tumor types, including breast (both), gastrointestinal (DAB2IP), colorectal, lung, and ovarian cancer (RASAL2) [56,57,58,59,60,61]. This evidence concerns the gene DAB2IP and ovarian carcinoma.